logo
Plus   Neg
Share
Email

Taro Pharma Receives Patent For T2007

Taro Pharmaceutical Industries Ltd. (TAROF.PK) Tuesday said the U.S. Patent and Trademark Office has issued the company a patent for its non-sedating barbiturate drug T2007, which is under development.

T2007 is the sodium salt of DPB (diphenyl barbituric acid). In previous Phase II studies, T2000, a prodrug or precursor of DPB, produced a functional improvement in patients with essential tremor, Taro had said in December. The FDA also granted an investigational new drug exemption to permit clinical studies on T2000 in the U.S.

Taro said today that plans for T2007 are currently directed at its use as an antiepileptic agent. In animal models, DPB has efficacy comparable to phenobarbital, a long-established clinical treatment for epilepsy.

Phenobarbital is the most commonly prescribed antiepileptic drug in the world, although its use is limited by its sedating side effects.

Last month, Taro received approval from the U.S. Food and Drug Administration for Fluorouracil Topical Cream USP, 5%. in February, the regulator approved its epilepsy drug Levetiracetam Tablets, 250 mg, 500 mg, 750 mg and 1000 mg.

Taro is trying to fend off an acquisition effort from India's Sun Pharmaceutical Industries Ltd.

TAROF.PK closed Monday's regular trade at $13.35, up from the prior close of $13.30, on 2,400 shares.

For comments and feedback contact: editorial@rttnews.com

Follow RTT
>